Can prognostic factors be used to direct therapy in chronic lymphocytic Leukemia?

Current Hematologic Malignancy Reports

Volumn 7, Issue 1, 2012, Pages 3-12

  Sellner, Leopold ^a   Dietrich, Sascha ^a   Dreger, Peter ^a   Glimm, Hanno ^b   Zenz, Thorsten ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

11q deletion; 17p deletion; Allogeneic; Chronic lymphocytic leukemia; CLL; Consolidation; Early treatment; IGHV.MRD; Maintenance; Predictive factors; TP53

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLAVOPIRIDOL; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; LENALIDOMIDE; OFATUMUMAB; PREDNISOLONE; PROTEIN P53; RITUXIMAB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER STAGING; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CONSOLIDATION CHEMOTHERAPY; DISEASE COURSE; DRUG CHOICE; DRUG MEGADOSE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; INFECTION; MEDICAL DECISION MAKING; PROGNOSIS; REVIEW; TREATMENT PLANNING; GENETICS; IMMUNOLOGY; INDUCTION CHEMOTHERAPY; METHODOLOGY; MUTATION; PHENOTYPE; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STEM CELL TRANSPLANTATION; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859259807     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0110-1     Document Type: Review

References (76)

1. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-88. (Pubitemid 46211313)
2. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-80.
3. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-74. This work presents the effect of the addition of rituximab to FC on response, PFS, and OS in a large, prospective clinical trial. Additionally, response and outcome are demonstrated according to different prognostic parameters.
4. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2009:602-609.
5. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a reportfrom the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-56.
6. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-34.
7. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198-206. (Pubitemid 11064396)
8. Letestu R, Levy V, Eclache V, et al. Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. Blood. 2010;116(22):4588-90.
9. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol. 2011;8 (1):38-47.
10. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med.2000;343(26):1910-6. (Pubitemid 32064784)
11. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524-9. (Pubitemid 35403967)
12. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17(1):28-40.
13. Parker H, Rose-Zerilli MJ, Parker A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocyticleukemia. Leukemia. 2011;25(3):489-97.
14. Stilgenbauer S, Liebisch P, James MR, et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosomebands 11q22.3-923.1 in lymphoproliferative disorders. Proc Natl Acad Sci U S A. 1996;93(21):11837- 41. (Pubitemid 26347210)
15. Isobe M, Emanuel BS, Givol D, et al. Localization of gene forhuman p53 tumour antigen to band 17p13. Nature. 1986;320 (6057):84-5. (Pubitemid 16105254)
16. Zenz T, Mertens D, Dohner H, Stilgenbauer S. Importance of genetics in chronic lymphocytic leukemia. Blood Rev. 2011;25(3):131-7.
17. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473-9. This work analyses the response and survival of CLL patients with TP53 mutations after fludarabine-basedchemotherapy.
18. Stankovic T, Stewart GS, Fegan C, et al. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood. 2002;99(1):300-9.
19. Pettitt AR, Sherrington PD, Stewart G, et al. p53 dysfunction in Bcell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001;98(3):814-22.
20. Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 2007;25(34):5448-57. (Pubitemid 350232222)
21. Puente XS, PinyolM, Quesada V, et al.Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.Nature. 2011;475(7354):101-5. In this work, new recurrent mutations in CLL were identified with next-generation sequencing.
22. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389-401.
23. Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2011.
24. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478 (7367):64-9.
25. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association withprogression and fludarabine-refractoriness. Blood. 2011.
26. Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37-50.
27. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chroniclymphocytic leukemia. Blood. 1999;94(6):1840-7. (Pubitemid 29430399)
28. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocyticleukemia. Blood. 1999;94(6):1848-54. (Pubitemid 29430400)
29. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V (H)3-21 genes characterize a new subset of chronic lymphocyticleukemia. Blood. 2002;99(6):2262-4. (Pubitemid 34525519)
30. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent ofgeographic origin and mutational status. Blood. 2006;107 (7):2889-94.
31. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 isassociated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100(13):4609-14. (Pubitemid 35429705)
32. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764-75. (Pubitemid 36514707)
33. Matrai Z, Lin K, Dennis M, et al. CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. Blood.2001;97(6):1902-3. (Pubitemid 32217269)
34. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictorof disease progression in chronic lymphocytic leukemia. N Engl JMed. 2004;351(9):893-901. (Pubitemid 39096916)
35. Wierda WG, O'Brien S, Wang X, et al. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009;27 (10):1637-43. A multivariable model with characteristics predictingimportant clinical end points was developed in this article.
36. Zenz T, Frohling S, Mertens D, et al. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol. 2010;23(1):71-84.
37. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med.1998;338(21):1506-14.
38. Ferrajoli A, Keating MJ, O'Brien S, et al. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0to II chronic lymphocytic leukemia. Cancer. 2011;117(14):3182-6.
39. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-riskchronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 2008;113(8):2110-8.
40. Gribben JG. How I treat CLL up front. Blood. 2010;115(2):187-97.
41. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885-91. (Pubitemid 43156283)
42. Catovsky D, Richards S,Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370(9583):230-9. (Pubitemid 47069536)
43. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabineplus cyclophosphamide compared with fludarabine forpatients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7):793-8. (Pubitemid 350002879)
44. Ding W, Ferrajoli A. Evidence-based mini-review: the role ofalkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion. Hematology Am Soc Hematol Educ Program. 2010;2010:90-2.
45. Smith MR, Neuberg D, Flinn IW, et al. Incidence of therapyrelated myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine:long-term follow-up of US Intergroup Study E2997. Blood.2011;118(13):3525-7.
46. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatmentwith rituximab in symptomatic, untreated patients with B-cellchronic lymphocytic leukemia: results from Cancer and LeukemiaGroup B 9712 (CALGB 9712). Blood. 2003;101(1):6-14. (Pubitemid 36025880)
47. Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survivaland progression-free survival in chronic lymphocytic leukemia: longtermfollow-up of CALGB study 9712. J Clin Oncol. 2011;29(10):1349-55.
48. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol. 2008;26(31):5094-100.
49. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med. 2002;347(6):452-3. (Pubitemid 34851846)
50. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutationsand deletions. Blood. 2004;103(9):3278-81. (Pubitemid 38525651)
51. Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating highresponse rates in genetically high-risk disease. J Clin Oncol. 2009;27(35):6012-8.
52. Badoux XC, Keating MJ, Wierda WG. What is the best frontline therapy for patients with CLL and 17p deletion? Curr HematolMalig Rep. 2011;6(1):36-46.
53. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23(13):2971-9. (Pubitemid 46224116)
54. Bottcher S, Stilgenbauer S, Busch R, et al. Standardized MRDflow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparativeanalysis. Leukemia. 2009;23(11):2007-17.
55. Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression free and overall survival in chronic lymphocytic leukemia. A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2011; (in press).
56. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003;98(12):2657-63. (Pubitemid 37509530)
57. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidationwith alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL StudyGroup (GCLLSG). Leukemia. 2004;18(6):1093-101. (Pubitemid 38786968)
58. Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab asconsolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. JClin Oncol. 2006;24(15):2337-42. (Pubitemid 46630666)
59. Lin TS, Donohue KA, Byrd JC, et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol. 2010;28(29):4500-6.
60. Schweighofer CD, Ritgen M, Eichhorst BF, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009;144(1):95-8.
61. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematicreview and meta-analysis of randomized trials. J Natl Cancer Inst. 2009;101(4):248-55.
62. Del Poeta G, Del Principe MI, Buccisano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.Cancer. 2008;112(1):119-28.
63. Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.Blood. 2011;118(13):3489-98.
64. Stilgenbauer S, Cymbalista F, Leblond V, et al. Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed byAlemtuzumab Maintenance or Allo-SCT In CLL with 17p-or Refractory to Fludarabine -Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW. ASH Annual MeetingAbstracts. 2010;116(21):920.
65. Sorror ML, Storer BE, Maloney DG, et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood. 2008;111(1):446-52.
66. Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26(30):4912-20.
67. Caballero D, Garcia-Marco JA,Martino R, et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities(11q-and 17p-). Clin Cancer Res. 2005;11(21):7757-63. (Pubitemid 41611619)
68. Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol. 2005;23(15):3433-8.
69. Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116 (14):2438-47. This trial demonstrates that patients with and without 17p-show similar survival after alloSCT.
70. Zenz T, Dreger P, Dietrich S, et al. Allogeneic stem cell transplantation can overcome the adverse prognostic impact of tp53 mutation in chronic lymphocytic leukemia (CLL): Results from the GCLLSG CLL3x Trial. ASH Annual Meeting Abstracts. 2010;116(21):2357.
71. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21(1):12-7. (Pubitemid 44921829)
72. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with Rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG). ASH Annual Meeting Abstracts. 2009;114 (22):205.
73. Pettitt AR,Matutes E, Dearden C, et al. Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolonefor high-risk (17p-) CLL. Haematologica. 2009;94 (Suppl2):138. abstract 0351.
74. Parikh SA, Keating MJ, O'Brien S, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011;118(8):2062-8.
75. Mauro FR, Molica S, Cortelezzi A, et al. Efficacy and safety of a first line combined therapeutic approach for young CLL patientswith advanced or progressive disease stratified according to the biologic features: first analysis of the GIMEMA multicenter study LLC0405. ASH Annual Meeting Abstracts. 2010;116(21):2471.
76. Wierda WG, Kipps TJ, Durig J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocyticleukemia. Blood. 2011;117(24):6450-8.